ANDAORALTABLET
Approved
Oct 2017
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
P2Y 12 class of ADP receptors on platelets.
Indications (4)
thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromenon-ST-elevation myocardial infarction (NSTEMI) ( )rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndrome (ACS)non-ST-elevation myocardial infarction (NSTEMI)
Clinical Trials (5)
Disparities in the Proportion of Ticagrelor and Prasugrel-eligible Patients with Acute Coronary Syndrome in a Real-world Registry
Started Mar 2023
6,789 enrolled
Acute Myocardial Infarction
Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients
Started Jul 2022
1,656 enrolled
ST Elevated Myocardial InfarctionDual Antiplatelet Therapy
Prasugrel in Severe COVID-19 Pneumonia
Started Jul 2020
128 enrolled
COVID19Thrombosis
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
Started Oct 2018
204 enrolled
Acute Coronary Syndrome (ACS)
CRUSHed vs. Uncrushed Prasugrel in STEMI Patients Undergoing PCI
Started Nov 2017
729 enrolled
Cardiovascular Diseases